AI Article Synopsis
- Evaluation of single-agent gemcitabine in treating AIDS-associated Kaposi's sarcoma (KS) was conducted in a Kenyan cancer treatment program.
- A study reviewed 23 patients who previously failed first-line therapy and found that 22 responded positively to gemcitabine, with many showing no disease progression after treatment.
- The findings suggest gemcitabine is a promising treatment option in resource-limited settings and warrants further research for its effectiveness in treating AIDS-associated KS.
Article Abstract
Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program.
Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment.
Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression.
Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000292356 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regression of Clinically Diagnosed Ocular Kaposi Sarcoma Post-Initiation of Highly Active Antiretroviral Therapy.
Am J Trop Med Hyg
December 2024
Department of Ophthalmology, Faculty of Medical Sciences, The University of the West Indies, St. Michael, Barbados.
Kaposi sarcoma is a low-grade vascular neoplasm linked to the human herpesvirus 8, with the AIDS-associated epidemic variant being the most common and aggressive. Although Kaposi sarcoma more commonly affects the cutaneous tissues, lymph nodes, and visceral organs, it can also be present in ocular and ocular adnexal tissues. We report a case of a 58-year-old Indo-Caribbean woman living with AIDS who presented with a large upper eyelid mass that was clinically diagnosed as Kaposi sarcoma.
View Article and Find Full Text PDFAnalysis of the ubiquitin-modified proteome identifies novel host factors in Kaposi's sarcoma herpesvirus lytic reactivation.
J Virol
December 2024
Biological Sciences, Towson University, Towson, Maryland, USA.
Unlabelled: Kaposi's sarcoma herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma and is associated with primary effusion lymphoma (PEL), multicentric Castleman's disease, and two inflammatory diseases. KSHV-associated cancers are primarily associated with genes expressed during latency, while other pathologies are associated with lytic gene expression. The major lytic switch of the virus, Replication and Transcription Activator (RTA), interacts with cellular machinery to co-opt the host ubiquitin proteasome system to evade the immune response as well as activate the program of lytic replication.
View Article and Find Full Text PDFEarly Mortality and Health Care Costs in Patients Recently Diagnosed With Kaposi Sarcoma at the National Cancer Institute, Mexico City.
Open Forum Infect Dis
November 2024
Infectious Diseases Department, Instituto Nacional de Cancerología, Mexico City, Mexico.
Article Synopsis
- Kaposi sarcoma (KS) remains a common cancer in AIDS patients in Mexico, highlighting issues with early HIV diagnosis despite access to treatment.
- The study analyzed 18 cases of KS in HIV patients who died within 30 days of hospital admission, revealing a young median age of 31 and significant delays in both admission and HIV diagnosis.
- The findings emphasize the need for improved early detection strategies, as increased screening could reduce KS-related deaths and lead to savings in healthcare costs.
People living with HIV co-infected with the Kaposi Sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
J Med Virol
August 2024
Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Kaposi sarcoma (KS) is a neoplasm of vascular origin that promotes angiogenesis and the growth of endothelial cells triggered by the Kaposi Sarcoma-associated Herpes Virus (KSHV). When associated with HIV, KSHV becomes more aggressive and rapidly evolves. The HIV-1 TAT protein can be essential in developing AIDS-associated KS by promoting angiogenesis and increasing KSHV replication.
View Article and Find Full Text PDFDisseminated AIDS-associated Kaposi sarcoma without cutaneous involvement: a case report and review of literature.
Int Cancer Conf J
July 2024
Dermatology Unit, Department of Internal Medicine, Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria.
Article Synopsis
- * A case study is presented of a 23-year-old HIV-positive patient who displayed unusual symptoms like cervical lymphadenopathy and respiratory issues, leading to a diagnosis of KS after histology confirmed it.
- * The patient, who was undergoing antiretroviral therapy, unfortunately passed away before starting chemotherapy, highlighting the aggressive nature of KS without typical symptoms and the need for heightened awareness in similar HIV cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!